Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Addict Biol. 2020 Dec 15;26(4):e12994. doi: 10.1111/adb.12994

Figure 5. Adolescent oxycodone exposure regulates gene expression at 1-day of withdrawal in the VTA.

Figure 5.

A.) Timeline of oxycodone withdrawal (WD) and tissue collection. B.) Adolescent oxycodone exposure activates Nr4a2 (Two-way ANOVA, n=6 per group, Interaction: F (1,20) = 22.98, p=0.0001; Drug: F1,20 = 18.21, p=0.0004; Age of Exposure F (1,20) = 18.21, p=0.0004; followed by Sidak’s multiple comparisons test, Adolescent Saline vs. Oxycodone, p<0.0001; Adult Saline vs. Oxycodone, p=0.999). C.) No significant difference in Cartpt expression following adolescent or adult oxycodone exposure (Two-way ANOVA, n=6 per group Interaction: F1,20 = 0.371, p=0.549; Drug: F1,20 = 0.371, p=0.549; Age of Exposure F1,20 = 0.011, p=0.917). D.) Dat is activated following adolescent oxycodone exposure (Two-way ANOVA, Interaction: F1,19 = 8.010, p=0.017; Drug: : F1,19 = 4.175, p=0.052; Age of Exposure : F1,19 = 8.010, p=0.0176; followed by Sidak’s multiple comparisons test, Adolescent Saline vs. Oxycodone, p=0.004; Adult Saline vs. Oxycodone, p=0.834). E.) Th is activated following adolescent oxycodone exposure when compared to saline. (Two-way ANOVA, Interaction: : F1,19 = 7.499, p=0.0131; Drug: : F1,19 = 7.097, p=0.015; Age of Exposure : F1,19 = 7.498, p=0.013; followed by Sidak’s multiple comparisons test, Adolescent Saline vs. Oxycodone, p=0.002; Adult Saline vs. Oxycodone, p=0.834). F.) No significant difference in H3K27me3 enrichment at the Nr4a2 promoter following adolescent or adult oxycodone exposure (Two-way ANOVA, Interaction: F1,20 = 0.396, p=0.536; Drug: F1,20 = 0.616, p=0.447; Age of Exposure F1,20 = 0.616, p=0.447). G.) No significant difference in H3K27me3 enrichment at the Cartpt promoter following adolescent or adult oxycodone exposure (Two-way ANOVA, Interaction: F1,20 = 0.111, p=0.741; Drug: F1,20 = 0.111, p=0.741; Age of Exposure F1,20 = 0.410, p=0.523). H.) No significant difference in H3K27me3 enrichment at the Dat promoter following adolescent or adult oxycodone exposure (Two-way ANOVA, Interaction: F1,17 = 0.067, p=0.7978; Drug: F1,17 = 0.028, p=0.884; Age of Exposure F1,17 = 0.410, p=0.7971). I.) No significant difference in H3K27me3 enrichment at the Th promoter following adolescent or adult oxycodone exposure (Two-way ANOVA, Interaction: F1,19 = 1.340, p=0.7184; Drug: F1,19 = 0.444, p=0.5130; Age of Exposure: F1,19 = 0.1340, p=0.7184). All data normalized to GAPDH relative to saline age-matched controls. n = 5–6 mice per group. Error bars represent S.E.M. *p<.05 relative to saline.